Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized placebo-controlled trial of lapatinib in HER2-positive ductal carcinoma in situ
2006-006619-64Phase 2Terminated
- Sponsor
- Manchester University NHS Foundation Trust
- Start
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in ductal carcinoma in situ (DCIS) and breast cancer comparing Lapatinib with Placebo (2 arms). Primary endpoints: Reduction in epithelial proliferation and Increase in apoptosis. Started Feb 2008; status: terminated.
02
Drugs
lapatinib
03
Conditions
ductal carcinoma in situ (DCIS)breast cancer
Beyond the preview
Go deeper on 2006-006619-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006619-64.